Gastrectomy Clinical Trial
Official title:
The Metabolic Consequences of Gastrointestinal Surgery
Surgery on the gastrointestinal (GI) tract results in profound changes to the metabolic profile. This is well described, including the rapid resolution of diabetes seen after bariatric surgery. The underlying pathophysiology, and incidence in lean patients undergoing surgery for cancer, is somewhat less described. The investigators plan to assess the symptomatic and glycaemic profile, as well as causative pathways, for metabolic symptoms in patients after surgery on the GI tract. The investigators will use glucose tolerance tests, physiological challenges with somatostatin analogues and antibiotics, and assess tissue transcriptomic changes.
The role of the gut hormone axis in glucose control is of significant interest due to its
proven translational impact in diabetes management. It is also significantly altered by
gastric surgery, a procedure that can lead to deleterious symptoms (dumping syndrome) in
lean, non-diabetic patients. The investigators will study a unique cohort of young, lean
patients undergoing surgery for the prevention of gastric cancer, as well as patients
undergoing surgery for gastric and oesophageal cancer, to further understand the regulation
and pathophysiological role of the gut hormone axis. The prophylactic patient population will
be recruited from the pool of patients with a genetic mutation conferring a high lifetime
risk of gastric cancer (Hereditary Diffuse Gastric Cancer) for whom Addenbrooke's Hospital
provides a national clinical service. The investigators aim to define the causative
physiological pathways for dumping syndrome in this group and expand our body of knowledge of
gut hormones and their role in glucose homeostasis and eating behaviour.
It has been suspected for some years that surgery has more profound physiological effects
than simple anatomical rearrangement, however recent developments in bariatric surgery have
brought this to the fore. The era of surgical treatment of peptic ulcer disease resulted in a
large cohort of patients undergoing gastric surgery and suffering post-operative dumping
symptoms. These include symptoms attributed to hypovolaemia immediately after a meal,
followed by hypoglycaemia within a few hours. There was a significant hiatus in the study of
dumping syndrome after the decline of surgery for ulcer disease in the 1980s. The major
improvement in long-term survival after surgery for oesophageal and gastric cancer seen in
the 21st Century, coupled with the identification of high risk familial cohorts who now
undergo prophylactic gastrectomy, has led to a growing cohort of long-term survivors after
gastrectomy. This presents the significant challenge of defining and managing the ongoing,
quality of life-limiting metabolic consequences of gastrointestinal surgery. The late dumping
symptoms suffered by this patient cohort include paradoxical post-prandial hypoglycaemia,
likely resulting from an excessive insulin response to particular components of ingested
food.
There is also a population of patients undergoing oesophagectomy for malignant or
pre-malignant conditions of the oesophagus, who receive post-operative nutrition through a
feeding tube sited through the abdominal wall and entering the jejunum approximately 1 metre
from its origin. This group of patients suffer similar metabolic changes to those undergoing
gastrectomy, and provide a unique opportunity to study the differential response to nutrients
administered orally or more distally. This could elucidate the role of any proximal gut
hormones in glucose homeostasis.
The recent expansion in understanding of the metabolic effects of surgery has largely been
driven by the study of bariatric (better termed metabolic) surgery. It is well known that
Roux-en-Y gastric bypass (RYGB) can result in early remission of diabetes in 85% of cases and
elevated levels of gut hormones such as glucagon-like peptide 1 (GLP-1), but there is
considerable debate around whether the gut hormones changes contribute to the reductions in
plasma glucose and appetite after surgery. Whereas studies in rodent models appear to
indicate that gut hormones are largely redundant after bypass surgery, data from humans
strongly support the idea that increased post-prandial GLP-1 and Peptide YY (PYY) levels
underlie improvements in insulin secretion and reduced appetite. Studies from bariatric
cohorts are confounded by the requirement for dietary restriction before surgery and massive
weight loss after surgery.
Multiple studies have measured the baseline and stimulated levels of circulating gut hormones
after RYGB in obese subjects. Elevated levels of GLP-1 and PYY and reduced levels of ghrelin
have been reported in most studies, and variable results have been found for
glucose-dependent insulinotropic peptide (GIP), cholecystokinin (CCK) and pancreatic
polypeptide (PP).
Fewer studies have addressed the changes in gut hormone secretion after gastrectomy in lean
subjects. Limited studies have demonstrated changes in GLP-1 secretion. Literature on the
experimental approach to dumping pathways is largely limited to case reports or small series
but indicates a role for the glucose-insulin axis.
The role of gut microbiota in determining host metabolism is a topical area of interest,
following discoveries that lean and obese phenotypes can be transferred by gut microbial
transplantation in rodent models. Despite the excitement surrounding this area, it remains a
highly controversial research field, and the extent to which the human microbiome influences
energy metabolism is hotly debated. A variety of microbial metabolites, including short chain
fatty acids and indole, however, modulate gut hormone secretion, and likely contribute to
basal gut hormone release in the fasting state. An interesting question that has not
previously been addressed is whether gut hormone secretion becomes more dependent on
microbial metabolism after bypass surgery, either because resident colonic bacteria are
supplied with an increased load of fermentable nutrients, or because of increased bacterial
growth in the proximal intestine (small intestinal bacterial overgrowth). It is, however,
well established that microbial metabolism is altered in some post-surgical patients, as
assessed non-invasively by the appearance of raised hydrogen or methane levels in exhaled
breath. It is also possible that the differing pool of bacteria between people may contribute
to a varied metabolic phenotype - it is therefore important to characterise the microbiome to
assess changes arising due to surgery or antibiotic treatment.
Beyond the purely physiological effects of surgery, there is an increasing understanding that
removal of the stomach or oesophagus has a profound effect on a person's appetite and eating
behaviour. This likely results from the central action of gut derived hormones, and is an
area of significant interest in the obesity field. Anecdotally, post-gastrectomy patients
frequently report minimal appetite and significant changes in their food preferences. At
present, this has not been characterised in a scientifically rigorous fashion. A variety of
tools exist to assess the motivation and impulsivity of a person's relationship to food in a
non-invasive fashion, which can be administered from home, or as an adjunct to a gut hormone
secretion test.
Previous studies from the investigators' group and beyond have demonstrated that L cells, the
prime enteroendocrince cells (EECs) secreting GLP-1, directly sense glucose uptake and have
receptors for bile acids and short chain free fatty acids (bacterial fermentation products of
carbohydrates). Each of these pathways could theoretically contribute to the enteroendocrine
detection of ingested carbohydrate, but the relative importance of the different sensory
mechanisms before, as well as after, GI surgery is unknown.
Overall, this proposed study of gut hormone secretion and metabolism in the lean population
will define the causative pathways of dumping syndrome and provide a model for the study of
post-operative gut hormone changes without the confounding effects of massive weight loss. In
turn, this will expand knowledge of the physiological pathways underlying gut hormone
secretion and their role in glucose homeostasis, with the potential to offer new therapeutic
and research targets in diabetes and obesity care, as well as in this patient cohort.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04422236 -
A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery
|
||
Completed |
NCT00827931 -
Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
|
Phase 4 | |
Completed |
NCT01257711 -
A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
|
N/A | |
Not yet recruiting |
NCT06062225 -
Protocol for Comparing the Efficacy of Three Reconstruction Methods of the Digestive Tract After Proximal Gastrectomy
|
N/A | |
Completed |
NCT00885781 -
Efficacy and Safety Comparison Between SMOFlipid and Lipovenoes MCT
|
Phase 4 | |
Not yet recruiting |
NCT05071755 -
Gastrectomy Outcomes in Elderly Patients
|
||
Recruiting |
NCT04798820 -
The Effect of Intensive Dietary Education on Nutritional Status After Gastrectomy(SING)
|
N/A | |
Not yet recruiting |
NCT04191564 -
Effect of Anesthetic Conditions on Stapling Thickness and Quality
|
N/A | |
Recruiting |
NCT04295473 -
Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
|
N/A | |
Recruiting |
NCT02068833 -
Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study
|
N/A | |
Recruiting |
NCT01142271 -
Comparison of Billroth-I and Roux-en-Y Reconstruction After Distal Subtotal Gastrectomy
|
Phase 3 | |
Completed |
NCT03939819 -
Endoscopic vs. Suction Device Calibration in Sleeve Gastrectomy
|
N/A | |
Recruiting |
NCT01657812 -
A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy
|
Phase 4 | |
Withdrawn |
NCT00622804 -
Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy
|
Phase 3 | |
Recruiting |
NCT03708783 -
Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGC
|
N/A | |
Recruiting |
NCT06403540 -
The Impact of Laparotomy and Analgesia Methods on Diaphragm
|
||
Completed |
NCT03436082 -
Post-Market Surveillance With a Novel mHealth Platform
|
||
Recruiting |
NCT06058442 -
The Pancreatic Enzymes After Gastrectomy Trial
|
Phase 3 | |
Unknown status |
NCT02503826 -
The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery
|
Phase 4 |